BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suzuki S, Esaki M, Kusano C, Ikehara H, Gotoda T. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World J Gastroenterol 2019; 25(16): 1907-1912 [PMID: 31086459 DOI: 10.3748/wjg.v25.i16.1907] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Shao Y, Lin Y, Wang B, Miao M, Ye G. Antibiotic resistance status of helicobacter pylori strains isolated from initial eradication patients in Ningbo, China, from 2017 to 2021. Helicobacter 2022;:e12920. [PMID: 35939548 DOI: 10.1111/hel.12920] [Reference Citation Analysis]
2 Zou X, Hu J, Zhao M, Qin C, Zhu Y, Tian G, Cai J, Seeberger PH, Yin J. Chemical Synthesis of the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum. J Am Chem Soc 2022. [PMID: 35939326 DOI: 10.1021/jacs.2c03068] [Reference Citation Analysis]
3 Gao W, Teng G, Wang C, Xu Y, Li Y, Cheng H. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China. Helicobacter 2022;:e12918. [PMID: 35877765 DOI: 10.1111/hel.12918] [Reference Citation Analysis]
4 Ortiz-ramírez P, Hernández-ochoa B, Ortega-cuellar D, González-valdez A, Martínez-rosas V, Morales-luna L, Arreguin-espinosa R, Castillo-rodríguez RA, Canseco-ávila LM, Cárdenas-rodríguez N, Pérez de la Cruz V, Montiel-gonzález AM, Gómez-chávez F, Gómez-manzo S. Biochemical and Kinetic Characterization of the Glucose-6-Phosphate Dehydrogenase from Helicobacter pylori Strain 29CaP. Microorganisms 2022;10:1359. [DOI: 10.3390/microorganisms10071359] [Reference Citation Analysis]
5 Aniceto N, Bonifácio VDB, Guedes RC, Martinho N. Exploring the Chemical Space of Urease Inhibitors to Extract Meaningful Trends and Drivers of Activity. J Chem Inf Model 2022. [PMID: 35666858 DOI: 10.1021/acs.jcim.2c00150] [Reference Citation Analysis]
6 Gudina EK, Amare H, Ali S, Berhane Arefayine M, Tewolde D, Tesfaye Eshete M, Jebena MG, Wieser A, Froeschl G, Tesfaye M, Desalegn H, Gashaw M, Granito A. Diagnostic Challenges of Helicobacter pylori Infection in Ethiopia: A Community-Based Cross-Sectional Study. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-8. [DOI: 10.1155/2022/4013020] [Reference Citation Analysis]
7 Inokuchi K, Mori H, Matsuzaki J, Hirata K, Harada Y, Saito Y, Suzuki H, Kanai T, Masaoka T. Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐line Helicobacter pylori eradication regimen. Helicobacter. [DOI: 10.1111/hel.12900] [Reference Citation Analysis]
8 Araújo GRL, Marques HS, Santos MLC, da Silva FAF, da Brito BB, Correa Santos GL, de Melo FF. Helicobacter pylori infection: How does age influence the inflammatory pattern? World J Gastroenterol 2022; 28(4): 402-411 [DOI: 10.3748/wjg.v28.i4.402] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Huang JG, Lim SYS, Aw MM, Quak SH. Antibiotic resistance patterns and therapeutic outcomes of pediatric Helicobacter pylori infection in a high-migrant Singaporean cohort. Helicobacter 2021;:e12868. [PMID: 34958710 DOI: 10.1111/hel.12868] [Reference Citation Analysis]
10 Tian D, Gou X, Jia J, Wei J, Zheng M, Ding W, Bi H, Wu B, Tang J. New diketopiperazine alkaloid and polyketides from marine-derived fungus Penicillium sp. TW58-16 with antibacterial activity against Helicobacter pylori. Fitoterapia 2021;156:105095. [PMID: 34896204 DOI: 10.1016/j.fitote.2021.105095] [Reference Citation Analysis]
11 Yu J, Yang P, Qin X, Li C, Lv Y, Wang X. Impact of smoking on the eradication of Helicobacter pylori. Helicobacter 2021;:e12860. [PMID: 34708484 DOI: 10.1111/hel.12860] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Sousa C, Ferreira R, Azevedo NF, Oleastro M, Azeredo J, Figueiredo C, Melo LDR. Helicobacter pylori infection: from standard to alternative treatment strategies. Crit Rev Microbiol 2021;:1-21. [PMID: 34569892 DOI: 10.1080/1040841X.2021.1975643] [Reference Citation Analysis]
13 Wojtyś MI, Jaźwiec R, Kazazić S, Leščić Ašler I, Knežević P, Aleksić Sabo V, Luić M, Jagusztyn-Krynicka EK, Bzowska A. A comprehensive method for determining cellular uptake of purine nucleoside phosphorylase and adenylosuccinate synthetase inhibitors by H. pylori. Appl Microbiol Biotechnol 2021;105:7949-67. [PMID: 34562116 DOI: 10.1007/s00253-021-11510-9] [Reference Citation Analysis]
14 Mladenova I. Clinical Relevance of Helicobacter pylori Infection. J Clin Med 2021;10:3473. [PMID: 34441769 DOI: 10.3390/jcm10163473] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
15 Sasaki Y, Abe Y, Shoji M, Mizumoto N, Takeda H, Oizumi H, Yaoita T, Sawada N, Yamagishi K, Saito E, Watanabe M, Ishizawa K, Konta T, Kayama T, Tsugane S, Ueno Y, Inoue M. Reliability of self-reported questionnaire for epidemiological investigation of Helicobacter pylori eradication in a population-based cohort study. Sci Rep 2021;11:15605. [PMID: 34341428 DOI: 10.1038/s41598-021-95124-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Zou PY, Hu J, Zhao JT, Zhao Z, Mei H, Yang J, Zhu YJ, Zhang Y, Lan CH. 10-Day and 14-day high-dose dual therapy for the treatment of Helicobacter pylori: A propensity score matching analysis. Helicobacter 2021;:e12833. [PMID: 34318966 DOI: 10.1111/hel.12833] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
17 Li XH, Huang YY, Lu LM, Zhao LJ, Luo XK, Li RJ, Dai YY, Qin C, Huang YQ, Chen H. Early genetic diagnosis of clarithromycin resistance in Helicobacter pyloriWorld J Gastroenterol 2021; 27(24): 3595-3608 [PMID: 34239272 DOI: 10.3748/wjg.v27.i24.3595] [Reference Citation Analysis]
18 Bhat S, Nunes D. Pharmacist-Managed Helicobacter pylori Treatment Service Within a Gastroenterology Clinic: Workflow and Real-World Experiences. Ann Pharmacother 2021;:10600280211021501. [PMID: 34049441 DOI: 10.1177/10600280211021501] [Reference Citation Analysis]
19 Kittisenachai S, Rojpibulstit P, Vilaichone RK, Gamnarai P, Phaonakrop N, Suealek N. FBPAII and rpoBC, the Two Novel Secreted Proteins Identified by the Proteomic Approach from a Comparative Study between Antibiotic-Sensitive and Antibiotic-Resistant Helicobacter pylori-Associated Gastritis Strains. Infect Immun 2021;89:e00053-21. [PMID: 33782154 DOI: 10.1128/IAI.00053-21] [Reference Citation Analysis]
20 Eto H, Suzuki S, Kusano C, Ikehara H, Ichijima R, Ito H, Kawabe K, Kawamura M, Yoda Y, Nakahara M, Gotoda T. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Helicobacter 2021;26:e12788. [PMID: 33580612 DOI: 10.1111/hel.12788] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
21 Camorlinga-Ponce M, Gómez-Delgado A, Aguilar-Zamora E, Torres RC, Giono-Cerezo S, Escobar-Ogaz A, Torres J. Phenotypic and Genotypic Antibiotic Resistance Patterns in Helicobacter pylori Strains From Ethnically Diverse Population in México. Front Cell Infect Microbiol 2020;10:539115. [PMID: 33643927 DOI: 10.3389/fcimb.2020.539115] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
22 Ma J, Qiu J, Wang S, Ji Q, Xu D, Wang H, Wu Z, Liu Q. A Novel Design of Multi-epitope Vaccine Against Helicobacter pylori by Immunoinformatics Approach. Int J Pept Res Ther 2021;:1-16. [PMID: 33424523 DOI: 10.1007/s10989-020-10148-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Yarmohammadi M, Yadegar A, Ebrahimi MT, Zali MR. Effects of a Potential Probiotic Strain Lactobacillus gasseri ATCC 33323 on Helicobacter pylori-Induced Inflammatory Response and Gene Expression in Coinfected Gastric Epithelial Cells. Probiotics Antimicrob Proteins 2021;13:751-64. [PMID: 33206342 DOI: 10.1007/s12602-020-09721-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
24 Roszczenko-Jasińska P, Wojtyś MI, Jagusztyn-Krynicka EK. Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets. Appl Microbiol Biotechnol 2020;104:9891-905. [PMID: 33052519 DOI: 10.1007/s00253-020-10945-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
25 Feng XY, Zhang Y, Deng B. Progress in research of high-dose dual therapy as an eradication protocol for Helicobacter pylori infection. Shijie Huaren Xiaohua Zazhi 2020; 28(17): 847-851 [DOI: 10.11569/wcjd.v28.i17.847] [Reference Citation Analysis]
26 Salehi N, Attaran B, Zare-Mirakabad F, Ghadiri B, Esmaeili M, Shakaram M, Tashakoripour M, Eshagh Hosseini M, Mohammadi M. The outward shift of clarithromycin binding to the ribosome in mutant Helicobacter pylori strains. Helicobacter 2020;25:e12731. [PMID: 32794288 DOI: 10.1111/hel.12731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Boyanova L, Markovska R, Hadzhiyski P, Kandilarov N, Mitov I. Rifamycin use for treatment of Helicobacter pylori infection: a review of recent data. Future Microbiol 2020;15:1185-96. [PMID: 32954842 DOI: 10.2217/fmb-2020-0084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Mashak Z, Jafariaskari S, Alavi I, Sakhaei Shahreza M, Safarpoor Dehkordi F. Phenotypic and Genotypic Assessment of Antibiotic Resistance and Genotyping of vacA, cagA, iceA, oipA, cagE, and babA2 Alleles of Helicobacter pylori Bacteria Isolated from Raw Meat. Infect Drug Resist 2020;13:257-72. [PMID: 32099418 DOI: 10.2147/IDR.S233612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]